Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.

Meet Our Team

A combined 150+ years of experience in the healthcare industry.

learn more

See Our Portfolio

$1.8 billion in assets, with a track record of investing and returning capital since 2000.

learn more

Latest News

Atreca Announces Expansion of Preclinical Pipeline

April 5, 2022
SAN CARLOS, CA - April 05, 2022 -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on…
READ MORE

BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

April 3, 2022
PALO ALTO, CA – April 3, 2022 — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced updated data…
READ MORE

CIDARA THERAPEUTICS ANNOUNCES THE COMPLETION OF DOSING THE FIRST COHORT OF HEALTHY VOLUNTEERS IN THE PHASE 1 TRIAL OF CD388 IN DEVELOPMENT FOR UNIVERSAL PREVENTION AND TREATMENT OF SEASONAL AND PANDEMIC INFLUENZA

March 31, 2022
SAN DIEGO, CA - March 31, 2022 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing…
READ MORE